Event Type: Q1 FY27 Earnings Conference Call
Date and Time: July 24, 2026 at 5:00 PM IST
Purpose: To discuss Q1 FY27 results followed by an interactive Q&A session
Host: The call will be hosted by DAM Capital Advisors
Management Participants: Not explicitly mentioned in the disclosure
Availability of Materials: No specific mention of presentation decks, transcripts, or recordings being made available
UPSI Compliance: The document serves as a formal intimation to exchanges but does not explicitly state whether unpublished price sensitive information will be shared
Financial Period: Q1 FY27 (April-June 2026)
Forward-looking Statements: No specific forward-looking statements or strategic themes referenced in this announcement
Additional Notes Section
Attachments: The letter mentions an enclosure ("Encl: A/a") which appears to be the conference call invite details
Financial Data Disclosure: No financial data or results were disclosed in this announcement
Dial-in Details: Multiple international dial-in numbers provided:
- Primary India: +91 22 6280 1384
- Secondary India: +91 22 7115 8285 (Available all over India)
- Singapore: +8001012045
- Hong Kong: +800964448
- USA: +18667462133
- UK: +08081011573
- Diamond Pass: Event Link
Contact Information:
- Investor Relations: Vivek Kumar, T +91 40 3980 4366, investorrelations@lauruslabs.com
- Media Relations: Karthik C, T +91 40 3980 4380, mediarelations@lauruslabs.com
Company Background: Laurus Labs is described as a research and development driven pharmaceutical and biotech company with global leadership in APIs including Anti-retroviral, Oncology, Cardiovascular, and Gastro therapeutics. Employs over 8,126 people including 3,134+ scientists, operates 15 facilities approved by global regulators. FY2026 annual revenue: ₹6,813 crore.